Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response
- 1 September 2001
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (17) , 1307-1314
- https://doi.org/10.1038/sj.gt.3301501
Abstract
Vectors based on Semliki Forest virus (SFV) have been widely used in vitro and in vivo to express heterologous genes in animal cells. In particular, the ability of recombinant SFV (rSFV) to elicit specific, protective immune responses in animal models suggests that rSFV may be used as a vaccine vehicle. In this study, we examined the distribution of rSFV in vivo by immunohistochemistry and RT-PCR after intravenous, intramuscular and subcutaneous injection of rSFV particles and related this to the degree of cytotoxic T lymphocyte (CTL) responses and frequency of specific T cells detected by MHC-I tetramers. We found that after i.v. injection, rSFV-RNA was distributed to a variety of different tissues, whereas it was confined locally after i.m. and s.c. injections. The persistence of the rSFV vector was transient, and no viral RNA could be detected 10 days after inoculation. All tested routes of immunization generated significant levels of antigen-specific CTL responses and increased numbers of specific CD8+ T cells, as detected by tetramer binding. The distribution of antigen-specific CTLs correlated with the in vivo distribution pattern of rSFV, with a highest frequency in the spleen or local lymph node, depending on the injection route.Keywords
This publication has 32 references indexed in Scilit:
- Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particlesGene Therapy, 2000
- Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokineGene Therapy, 2000
- Langerhans Cells Migrate to Local Lymph Nodes Following Cutaneous Infection with an ArbovirusJournal of Investigative Dermatology, 2000
- Evaluation of recombinant alphaviruses as vectors in gene therapyGene Therapy, 2000
- Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A geneGene Therapy, 1999
- Alphaviruses as Tools in Neurobiology and Gene TherapyJournal of Receptors and Signal Transduction, 1999
- REGULATORS OF APOPTOSIS ON THE ROAD TO PERSISTENT ALPHAVIRUS INFECTIONAnnual Review of Microbiology, 1997
- Expression of β-galactosidase in mouse brain: utilization of a novel nonreplicative Sindbis virus vector as a neuronal gene delivery systemGene Therapy, 1997
- Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogeneNature, 1993
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990